| Primary | Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6 | 12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition. | Full analysis set (FAS): all participants who were randomized and took at least 1 dose of randomized study medication. N = number of participants with ADAS-Cog 75 results at Week 6. | Posted | | Least Squares Mean | Standard Error | units on scale | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00018.07± 0.942
- OG00118.49± 0.939
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Difference from placebo. Analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week. | ANCOVA | | 0.3873 | ANCOVA model using unstructured covariance structure; Type I error rate for primary hypothesis was 5%; no adjustments made for multiplicity. | Mean Difference (Final Values) | -0.42 | | | 2-Sided | 95 | -1.37 | 0.53 | | | | No | Superiority or Other | | |
|
| Secondary | Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3 | 12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition. | FAS; N = number of participants with ADAS-Cog 75 results at Week 3. | Posted | | Least Squares Mean | Standard Error | units on scale | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3 | 11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition. | FAS. N = number of participants with ADAS-Cog 70 results at Week 3. | Posted | | Least Squares Mean | Standard Error | units on scale | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6 | 11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition. | FAS. N = number of participants with ADAS-Cog 70 results at Week 6. | Posted | | Least Squares Mean | Standard Error | units on scale | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6 | CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. | FAS; N = number of participants with a CGI-I score at Week 6. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Neuropsychiatric Inventory (NPI) Total Score at Week 3 | Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms * severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances. | FAS. N = number of participants with a NPI total score at Week 3. | Posted | | Least Squares Mean | Standard Error | scores on scale | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Neuropsychiatric Inventory (NPI) Total Score at Week 6 | Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms * severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances. | FAS. N = number of participants with a NPI total score at Week 6. | Posted | | Least Squares Mean | Standard Error | scores on scale | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1 | Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 [5000]) were excluded as reflecting responses that were abnormally slow. | FAS; N = number of participants with a CogState score for Detection at Week 1. | Posted | | Least Squares Mean | Standard Error | log10 millisecond | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3 | Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 [5000]) were excluded as reflecting responses that were abnormally slow. | FAS; N = number of participants with a CogState score for Detection at Week 3. | Posted | | Least Squares Mean | Standard Error | log10 millisecond | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6 | Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 [5000]) were excluded as reflecting responses that were abnormally slow. | FAS; N = number of participants with a CogState score for Detection at Week 6. | Posted | | Least Squares Mean | Standard Error | log10 millisecond | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1 | Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times. | FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 1. | Posted | | Least Squares Mean | Standard Error | errors | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3 | Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times. | FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 3. | Posted | | Least Squares Mean | Standard Error | errors | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6 | Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times. | FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 6. | Posted | | Least Squares Mean | Standard Error | errors | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1 | Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. | FAS; N = number of participants with a CogState score for One Back Working Memory at Week 1. | Posted | | Least Squares Mean | Standard Error | arcsine proportion correct | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3 | Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. | FAS; N = number of participants with a CogState score for One Back Working Memory at Week 3. | Posted | | Least Squares Mean | Standard Error | arcsine proportion correct | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6 | Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. | FAS; N = number of participants with a CogState score for One Back Working Memory at Week 6. | Posted | | Least Squares Mean | Standard Error | arcsine proportion correct | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1 | Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease [AD], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. | FAS; N = number of participants with a CogState score for Visual Learning at Week 1. | Posted | | Least Squares Mean | Standard Error | arcsine proportion correct | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3 | Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease [AD], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. | FAS; N = number of participants with a CogState score for Visual Learning at Week 3. | Posted | | Least Squares Mean | Standard Error | arcsine proportion correct | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6 | Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease [AD], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. | FAS; N = number of participants with a CogState score for Visual Learning at Week 6. | Posted | | Least Squares Mean | Standard Error | arcsine proportion correct | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1 | Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 [5000]) were excluded as reflecting responses that were abnormally slow. | FAS; N = number of participants with a CogState score for Identification at Week 1. | Posted | | Least Squares Mean | Standard Error | log10 millisecond | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3 | Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 [5000]) were excluded as reflecting responses that were abnormally slow. | FAS; N = number of participants with a CogState score for Identification at Week 3. | Posted | | Least Squares Mean | Standard Error | log10 millisecond | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |
| Secondary | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6 | Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 [5000]) were excluded as reflecting responses that were abnormally slow. | FAS; N = number of participants with a CogState score for Identification at Week 6. | Posted | | Least Squares Mean | Standard Error | log10 millisecond | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Varenicline | Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks. | | OG001 | Placebo | Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks. |
| |